🔗 Share this article

A shadow economy for unlicensed slimming drugs is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.

Investigational Treatment Acquiring Traction Via Social Media

The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its alleged weight-reducing effects. Viewers are encouraged to contact these profiles privately for supplier links, while also receiving discount codes.

Thriving Trade on Messaging Platforms

Additionally, a robust trade exists on messaging services, where communities with numerous of members share “before and after” photos, injection guides and assertions of rapid UK delivery. Sellers market the substance there before redirecting customers to WhatsApp for transactions.

Understanding The Experimental Drug

Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the next Ozempic.

Healthcare Professionals Express Worries

Nevertheless, physicians and chemists have warned that the distribution of what remains an unlicensed drug in the United Kingdom is worrisome and could lead to users administering products of unknown origin.

Several experts stated the popularity for the experimental drug could be connected to the increasing cost of licensed slimming treatments such as Mounjaro.

Legal Position and Implementation

Selling retatrutide on social media or Telegram is prohibited in the UK, as it is an unapproved medication that must not be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and supply can still violate medicines, advertising, and customer laws, potentially leading to fines, legal action or prison.

Service Reaction and Content Elimination

According to TikTok, the platform has taken down violative content and prohibited associated keywords and query recommendations. The organization stated it was committed to keeping the service safe and allocating resources in strengthening compliance measures.

Digital Marketplace Operations

Investigations also found communities with up to 9,000 members selling retatrutide using the platform's integrated search feature, which operates like a public directory. Entering “retatrutide” immediately displays groups with thousands of users, filled with images of weight loss, glowing reviews and detailed instructions for mixing or administering at home.

After minutes of entering one group, a seller shared contact information, where most transactions occur. The seller sent an instruction manual and promised delivery within two days. When asked whether the product was authentic, one seller said: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one asked about weight, health issues or previous experience.

Product Details and Pricing

Inside these groups, messages display dark colored packages with Royal Mail stickers, claiming to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at residence with purified liquid, or pre-filled injectors typically sold at 160 pounds for 20 milligrams. When questioned how much time a injector should be used, sellers give contradictory answers varying between a few weeks to “depends on your body”.

Platform Oversight and Safety Actions

A representative for Telegram stated it regularly monitored dangerous material on its service including content that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are administering materials they can’t verify. Although the research behind this drug is sound, these digital products may not include what they claim,” said Jason Murphy, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor connected the increase in interest to recent price rises for approved slimming drugs such as Mounjaro. “With prices rising, individuals are using online platforms. But counterfeit injections are extremely dangerous. You cannot know what’s contained or whether the conditions they were produced in was clean,” she said.

Her team has already seen patients harmed by personal administration from unverified suppliers. “We understand the disappointment, but buying from Telegram or communication platforms is taking chances with your health,” said Wyllie. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Statement

A representative from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Therefore at this time no one can market [it] for personal consumption,” they said, noting that any product “falsely representing itself as a company investigational product not yet approved … may subject patients to possibly significant health risks”.